For patients with bacterial infections, the sooner they are treated with the appropriate antibiotics, the…
karnottOctober 30, 2024
Editas Medicine is pushing its in vivo gene therapy strategy to the top of its…
karnottOctober 29, 2024
Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company developing positive functional modulators (PFMs), small molecule therapeutics…
karnottOctober 28, 2024
David Pellman, MD, and Matthew Vander Heiden, MD, PhD of Dana-Farber Cancer Institute have been…
karnottOctober 28, 2024
This week, we profile a recent publication in Nature Biotechnology by Dr. Rizwan Romee from…
karnottOctober 28, 2024
Researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center…
karnottOctober 25, 2024
AvenCell Therapeutics has secured $112 million in series B funds as the Novo Holdings-backed biotech…
karnottOctober 25, 2024
A Boston University–led nonprofit that’s taking on the growing threat of antibiotic-resistant bacteria has just…
karnottOctober 24, 2024
NYBC Ventures, a specialized fund focused on investments in blood and cellular technologies, announced today…
karnottOctober 24, 2024
